As part of the company’s Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, Bayer is giving a total of $1 million to seven research projects related to pulmonary hypertension. The awards are aimed at projects focused on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), which makes the…

In people experiencing a pulmonary embolism, higher-than-normal arterial stiffness at the time of hospital discharge increased the risk of pulmonary arterial hypertension (PAH) when evaluated one month later, according to a study in Italy. Given that this patient population is at risk of chronic thromboembolic pulmonary hypertension…

Intermediate-risk pulmonary arterial hypertension (PAH) patients may see their symptoms improve after switching from phosphodiesterase-5 inhibitors (PDE-5i) to Adempas (riociguat), results from the Phase 4 REPLACE clinical trial show. The transition to Adempas also appears to be a safer option than with PDE-5i maintenance therapy. The study, “Switching…

Can you imagine being denied something that could prolong your life? In a previous column, I interviewed adult pulmonary hypertension (PH) patients who are ineligible for transplant. Their responses were open, honest, and mature. But what if the patient is a child? How do parents cope with that kind…

Several proteins involved in vascular remodeling, metabolism, and oxidative stress are not properly regulated in endothelial cells from patients with chronic thromboembolic pulmonary hypertension (CTEPH), a study found. The study, “Protein network analyses of pulmonary endothelial cells in chronic thromboembolic pulmonary hypertension,” was published in the journal…

People with pulmonary hypertension are less likely to be referred to exercise therapy if they are of lower socioeconomic status or perceive more barriers to accessing such therapy, a study shows. These findings highlight the need for increased education about the benefits of exercise for people with pulmonary hypertension,…

A total of approximately 5.8 new cases per one million inhabitants was found to be the most accurate value for the worldwide incidence of pulmonary arterial hypertension (PAH), according to a review study. That incidence value — the rate of occurrence of new cases of a disease — ranged…

Soluble ST2 (sST2) protein could be an additional non-invasive biomarker for monitoring patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing interventional treatment with balloon pulmonary angioplasty (BPA), a study suggests. The study, “Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated…

The prolargin protein may serve as a biomarker for pulmonary arterial hypertension (PAH), allowing for earlier diagnosis and differentiating among different types of pulmonary hypertension (PH), according to a recent study. The study, “Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension,” was…

Lower quality of life in patients with pulmonary hypertension (PH) was found to be associated with higher burden experienced by their caregivers, according to a study conducted in Turkey. The study, “Caregiver Burden in Patients with Pulmonary Hypertension,” was published in the journal Clinical Nursing…

Long-term treatment with Bayer’s Adempas (riociguat) was safe and well-tolerated in people with pulmonary arterial hypertension (PAH), according to data from the real-world EXPERT study. These findings from clinical practice were consistent with those reported in previous clinical trials, supporting the therapy’s favorable safety profile. Data from EXPERT…

The Pulmonary Hypertension Association (PHA) is promoting several events throughout November — the Pulmonary Hypertension (PH) Awareness Month. This year, people are encouraged to discover the risk factors and symptoms of PH, and the challenges faced by those living with the disease, and their families. PH…